Zebinix non-inferior to current standard of care in epilepsy
Eisai and Bial’s epilepsy drug Zebinix has shown effectiveness on par with that of the current standard of care in newly diagnosed focal epilepsy patients.
Read More
Tag: Bial
Real world data back use of Eisai, Bial’s Zebinix in epilepsy
A pooled analysis of real-world data from over 2,000 patients with epilepsy has shown that Eisai and Bial’s Zebinix is safe and effective when switching from previous treatment with carbamazepine or oxcarbazepine.
Read More
EU regulators widen approval for Zebinix
The European Medicines Agency has cleared use of Bial and Eisai’s sodium channel blocker Zebinix for use as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy, widening its treatment scope in the region.
Read More
UK launch for Bial’s Parkinson’s drug
Patients with Parkinson’s disease in the UK can now potentially access a new option to treat motor fluctuations with the launch of Bial’s Ongentys across the country.
Read More
EU clears Bial’s new Parkinson’s drug
The European Commission has approved Bial’s Ongentys for Parkinson’s disease patients with motor fluctuations.
Read More
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
- Atrogi begins dosing first subjects in human trial of ATR-258
- R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatment
